Investigators have used base editing to create a treatment for multisystemic smooth muscle dysfunction syndrome, which has ...

Funded through a $17 million NIH grant, the program will try six strategies to combat HIV and advance the most promising.

The firm's commercialization push is fueled by $35.6 million from a recent Series C financing and a $15.5 million ...

Phase II/III data showed that advanced gastric cancer patients on anbenitamab and chemotherapy fared better than those on standard therapy.

Autonomous AI tools have great potential in supporting precision medicine, but developers are still figuring out how to deploy them in patient care.

NEW YORK – Lantern Pharma has a clearer vision of how it wants to study LP-184, a DNA-damaging small molecule, in pediatric ...

The agency said it will accept data from single-arm trials in its newly released Rare Disease Evidence Principles, but ...

Cambridge, Massachusetts-based Amylyx announced pricing of an underwritten public offering of 17,500,000 shares of its common stock at a public offering price of $10 per share. The firm has also ...

The company announced results from a Phase Ib trial of the drug as a first-line monotherapy for EGFR PACC-mutated NSCLC.

Some feel the guidance may encourage consistent follow-up of overall survival after accelerated approvals, but others remain focused on speeding new drugs to patients.

NEW YORK – Hemogenyx Pharmaceuticals on Friday said it has treated the final patient with relapsed or refractory FLT3-expressing acute myeloid leukemia (AML) in the first dosing cohort of a Phase I ...

NEW YORK – Immunotherapy developer Xilio Therapeutics will showcase new masked T-cell engagers in its clinical pipeline over the next two years, the company said this week while announcing second ...